Ask HopeStage to review this study with me
Study ID: NCT04085172. We help you review the study, but cannot decide medical eligibility.
CompletedNCT04085172
TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
This study is completed in the United States, in the United Kingdom, in Belgium, .... It is testing TAK-503 for ADHD.
ADHDDrugFrom 6 Years to 17 Years
Key information made simple
What is this study testing?
This study is testing whether TAK-503 may be useful for adolescents experiencing ADHD.
What would participation involve?
Participants may receive TAK-503, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Austria, Belgium, Germany.
Who is it mainly for?
This study appears to be mainly for adolescents with ADHD. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
The official record suggests in-person participation through a hospital, with sites including Harmonex Neuroscience Research in Dothan, Advanced Research Center, Inc in Anaheim, and Sun Valley Research Center, Inc in Imperial. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include safety concerns that need urgent care first and active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means the approach is being followed in broader real-world use.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: September 18, 2019
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States, United Kingdom, Belgium, ...
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT04085172
- Official title
- A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT04085172. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Austria.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Do I need to want to stop or reduce tobacco use to participate?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Shire, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT02059642
MG01CI 1400 mg Compared With Placebo for ADHD
This study is completed in the United States and in Israel. It is testing MG01CI 1400 mg Compared With Placebo for ADHD.
CompletedNCT00500149
Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD
This study is completed in the United States. It is testing time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD.
CompletedNCT02555150
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
This study is completed. It focuses on ADHD and currently lists study information in the United States.